Kenvue Option Alert: Sep 19 $23 Calls at the Ask: 7363 vs 20255 OI

Kenvue Option Alert: Sep 19 $23 Calls at the Ask: 7363 @ $1.31 vs 20255 OI; Ref=$21.94

Kenvue Option Alert: Sep 19 $23 Calls Sweep (35) near the Ask: 5790 vs 20255 OI

Kenvue Option Alert: Sep 19 $23 Calls Sweep (35) near the Ask: 5790 @ $1.23 vs 20255 OI; Ref=$21.86

Kenvue Option Alert: Sep 19 $23 Calls Sweep (4) near the Bid: 14894 vs 476 OI

Kenvue Option Alert: Sep 19 $23 Calls Sweep (4) near the Bid: 14894 @ $1.35 vs 476 OI; Ref=$22.16

Kenvue (NYSE:KVUE) Azioni

Kenvue

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Equities

News

Markets

AVGO

KVUE

MRVL

NVDA

QRVO

RIOT

SWKS

Il recente coinvolgimento di un importante investitore attivista ha stimolato un significativo rialzo delle azioni.

Questo titolo si impenna del 7% dopo il coinvolgimento di Starboard

Earnings

Large Cap

Guidance

Health Care

Movers

General

Le azioni di Kenvue, noto produttore di Listerine, salgono del 13,80% dopo solidi risultati finanziari del secondo trimestre.

Le azioni di Kenvue, produttore di Listerine, salgono dopo il Q2

Kenvue Inc

Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) sees FY2025 sales of $787.583 million-$804.163 million vs $805.84 million analyst estimate.

MBUU

Malibu Boats Sees FY2025 Sales $787.583M-$804.163M vs $805.84M Est

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) raises FY2025 Adj EPS guidance from $0.17-$0.22 to $0.18-$0.26 vs $0.18 analyst estimate. Raises FY2025 sales outlook from $680.00 million-$684.00 million to $680.00 million-$688.00 million vs $679.11 million estimate.

APPN

Appian Raises FY2025 Adj EPS Guidance from $0.17-$0.22 to $0.18-$0.26 vs $0.18 Est; Raises FY2025 Sales Guidance from $680.00M-$684.00M to $680.00M-$688.00M vs $679.11M Est

QTTB

Q32 Bio Q1 2025 EPS $(0.90) Up From $(6.33) YoY, Cash And Cash Equivalents Of $65.5M As Of March 31, 2025 Expected To Provide Financial Runway Into 2H 2026

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) is looking for Q2 Adj EPS of $(0.15)-$(0.11) vs $(0.13) analyst estimate. sees sales of $158.000 million-$162.000 million vs $162.16 million analyst estimate.

Appian Sees Q2 Adj EPS $(0.15)-$(0.11) vs $(0.13) Est; Sees Sales $158.000M-$162.000M vs $162.16M Est

Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) sees FY2025 sales of $8.600 billion-$8.700 billion vs $8.56 billion analyst estimate.

ATUS

Altice USA Sees FY2025 Sales $8.600B-$8.700B vs $8.56B Est

Mr. Rees continued, "While we are pleased by the performance of our overall business in April, the new global trade environment as well as business and consumer uncertainty, has made it challenging to predict how consumers may respond in the future. Amid this heightened operating backdrop, we are withdrawing our guidance for 2025. We are committed to remaining transparent to our investment community, our consumers, and our customers as we work to chart a winning course."

CROX

Crocs CEO Mr. Rees Said The Company Is Pleased With April's Performance But Is Pulling 2025 Guidance Amid Growing Uncertainty

Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) raises FY2025 sales outlook from $415.00 million-$435.00 million to $460.00 million-$475.00 million vs $499.51 million estimate.

DAVE

Dave Raises FY2025 Sales Guidance from $415.00M-$435.00M to $460.00M-$475.00M vs $499.51M Est

Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) affirms FY2025 sales outlook from $215.44 million-$219.19 million to $215.44 million-$219.19 million vs $216.90 million estimate.

AXGN

Axogen Affirms FY2025 Sales Guidance of $215.44M-$219.19M vs $216.90M Est

Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 220 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $2.15 billion which missed the analyst consensus estimate of $2.16 billion by 0.27 percent. This is a 4.40 percent decrease over sales of $2.25 billion the same period last year.

Earnings Misses

Altice USA Q1 EPS $(0.16) Misses $(0.08) Estimate, Sales $2.15B Miss $2.16B Estimate

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.03 by 333.33 percent. This is a 154.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $166.43 million which beat the analyst consensus estimate of $163.35 million by 1.88 percent. This is a 11.07 percent increase over sales of $149.84 million the same period last year.

Earnings Beats

Appian Q1 Adj. EPS $0.13 Beats $0.03 Estimate, Sales $166.43M Beat $163.35M Estimate

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will no longer sell the range extender battery pack for its Cybertruck. The range extender would have let the vehicle achieve a range of over 500 miles.
What Happened: Customers took to social media to share details of an email they received from Elon Musk's company titled "Update to your Cybertruck Range Extender Order." Tesla influencer Sawyer Merritt shared a screenshot in a post on the social media platform X on Wednesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Tesla has cancelled the Cybertruck Range Extender. "We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full" <a href="https://t.co/yb1xOqecX2">pic.twitter.com/yb1xOqecX2</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1920253628012470621?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full." The email from Tesla said. The range extender was originally available for $16,000 as an extra battery pack that would be fitted on the Cybertruck's bed.
Why It Matters: The news comes in as Musk's EV giant is struggling to sell units of the Cybertruck. The company reportedly has over <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">10,000 units of unsold Cybertrucks</a> in its U.S. inventory.
In a bid to boost sales and appeal to a wider customer base, Tesla also revamped the truck's <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">marketing language and strategy </a>to position it as a utilitarian, rugged pickup truck.
Interestingly, the company recently offered <a href="https://www.benzinga.com/25/05/45245835/tesla-hands-out-free-1-year-supervised-fsd-trial-to-select-cybertruck-owners">select Cybertruck owners </a>a 1-year-long free trial of Supervised Full Self-Driving, provided that they subscribe to the service before the June 6, 2025, deadline.
Elsewhere, Tesla also launched a <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">cheaper, RWD version</a> of the truck, which offered longer range but missed out on some features like smaller wheels, reduced towing capacity and lower ground clearance. The model retails for $62,490 with the federal EV credit and offers 362 miles of range.
Price Action: TSLA is currently $280.80, gaining 1.66% in pre-market trading, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45244989/lucid-group-q1-2025-earnings-tesla-rival-announces-58-increase-in-deliveries-plans-to-introduce-a-mid-size-platform-in-2026">Tesla-Rival Lucid Announces 58% Increase In Deliveries, Plans To Introduce Mid-Size Platform In 2026</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Tech

TSLA

Elon Musk's Tesla Scraps Popular $16,000 Cybertruck Range Extender As Sales Dwindle In US

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025
Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting

CGEM

Cullinan Therapeutics Receives EMA Approval For CLN-978; Phase 1 Study In Active, Difficult-To-Treat Rheumatoid Arthritis To Initiate In Q2 2025

XERS

Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $255.00M-$275.00M to $260.00M-$275.00M vs $317.63M Est

Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) affirms FY2025 sales outlook from $47.60 million-$49.00 million to $47.60 million-$49.00 million vs $48.03 million estimate.

APYX

Apyx Medical Affirms FY2025 Sales Guidance of $47.60M-$49.00M vs $48.03M Est

BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) affirms FY2025 sales outlook from $125.00 million-$142.00 million to $125.00 million-$142.00 million vs $168.00 million estimate.

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Technology Affirms FY2025 Sales Guidance of $125.00M-$142.00M vs $168.00M Est

Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $0.79 by 213.92 percent. This is a 300 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $108.00 million which beat the analyst consensus estimate of $100.80 million by 7.14 percent. This is a 46.74 percent increase over sales of $73.60 million the same period last year.

Dave Q1 Adj. EPS $2.48 Beats $0.79 Estimate, Sales $108.00M Beat $100.80M Estimate

Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $48.56 million which beat the analyst consensus estimate of $48.32 million by 0.49 percent. This is a 17.36 percent increase over sales of $41.38 million the same period last year.

Axogen Q1 Adj. EPS $(0.02) Misses $0.02 Estimate, Sales $48.56M Beat $48.32M Estimate

BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 52.27 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $29.54 million which missed the analyst consensus estimate of $29.90 million by 1.18 percent. This is a 21.90 percent increase over sales of $24.24 million the same period last year.

BlackSky Technology Q1 EPS $(0.42) Beats $(0.45) Estimate, Sales $29.54M Miss $29.90M Estimate

AUTL

Autolus Therapeutics Q1 EPS $(0.26), Inline

Needham analyst Quinn Bolton maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and lowers the price target from $54 to $50.

Price Target

Analyst Ratings

IONQ

Needham Maintains Buy on IonQ, Lowers Price Target to $50

Press Releases

Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting

Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey

Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign

OGX® Haircare Introduces Shay Mitchell as First Global Brand Ambassador

Legal

KENVUE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Kenvue Inc. (NYSE: KVUE) and Encourages Long-Term KVUE Investors to Contact the Firm

Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

Kenvue Declares Quarterly Cash Dividend

Kenvue to Announce First Quarter 2025 Results on May 8, 2025

Kenvue Announces Chief Financial Officer Transition

Kenvue Reports First Quarter 2025 Results

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Upexi

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
12:49 PMFeb 19, 2025	CALL	$23.00	Sep 19, 2025	133	20087	7363	99	20255	TRADE	BULLISH
12:33 PMFeb 19, 2025	CALL	$23.00	Sep 19, 2025	133	6964	5790	34	20255	SWEEP	BULLISH
03:03 PMFeb 18, 2025	CALL	$23.00	Sep 19, 2025	133	20012	14894	4204	476	SWEEP	BEARISH

Comments

Kenvue

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO